IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

USA-based biotech IMMvention Therapeutix yesterday revealed it has entered into a strategic collaboration and license ...

IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

(MENAFN- GlobeNewsWire - Nasdaq) DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human ...

DURHAM, N.C., Jan. 22, 2025 (GLOBE NEWSWIRE) -- IMMvention Therapeutix, Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a ...

BMI OrganBank has secured a $3.5 million federal grant that will help the Winston-Salem company advance its kidney preservation technology and prepare for clinical trials.